Management of Hemolytic Uremic Syndrome-Thrombotic Thrombocytopenic Purpura Following Renal Transplant
Initial Diagnostic Workup
- The American Society of Clinical Oncology recommends obtaining a peripheral blood smear to identify schistocytes, which is critical for diagnosis, in patients with suspected Hemolytic Uremic Syndrome-Thrombotic Thrombocytopenic Purpura (HUS-TTP) following renal transplant 1
- The American Society of Clinical Oncology suggests measuring ADAMTS13 activity level and inhibitor titer to distinguish TTP from other forms of thrombotic microangiopathy in patients with HUS-TTP following renal transplant 1
- The American Society of Clinical Oncology recommends assessing hemolysis by measuring lactate dehydrogenase (LDH), haptoglobin, and indirect bilirubin in patients with HUS-TTP following renal transplant 1
- The American Society of Nephrology recommends evaluating renal function by measuring serum creatinine and urinalysis in patients with HUS-TTP following renal transplant 1
- The American Society of Transplantation recommends checking CMV serology as viral infection can trigger HUS in transplant recipients 2
Immediate Management Algorithm
- The American Society of Clinical Oncology recommends initiating therapeutic plasma exchange (PEX) with fresh frozen plasma according to existing TTP guidelines if ADAMTS13 activity is severely reduced or if there are life-threatening consequences in patients with HUS-TTP following renal transplant 1
- The American Society of Clinical Oncology suggests administering methylprednisolone 1 gram IV daily for 3 days, with the first dose given immediately after the first plasma exchange, in patients with HUS-TTP following renal transplant 1
Monitoring During Treatment
- The American Society of Clinical Oncology recommends monitoring platelet count, hemoglobin, and LDH daily to assess response to therapy in patients with HUS-TTP following renal transplant 1
- The American Society of Nephrology recommends monitoring graft function closely with daily serum creatinine during acute episode in patients with HUS-TTP following renal transplant 3, 4
Transfusion Management
- The American Society of Clinical Oncology recommends transfusing red blood cells only to relieve symptoms or achieve hemoglobin 7-8 g/dL in stable patients with HUS-TTP following renal transplant 1
- The American Society of Clinical Oncology suggests discussing with blood bank team before any transfusions that a patient with possible thrombotic microangiopathy is being treated 1
Alternative Immunosuppression Strategy
- The American Society of Nephrology recommends maintaining corticosteroids as part of baseline immunosuppression in patients with HUS-TTP following renal transplant 3, 4
- The American Society of Nephrology suggests continuing mycophenolate mofetil if tolerated, as antimetabolites are not implicated in HUS pathogenesis, in patients with HUS-TTP following renal transplant 3, 4
Additional Therapeutic Considerations
- The American Society of Clinical Oncology recommends considering rituximab (375 mg/m² weekly for 4 weeks) for acquired TTP in patients with severely reduced ADAMTS13 activity (<10%) following renal transplant 1
- The American Society of Clinical Oncology suggests considering caplacizumab if ADAMTS13 activity is low with inhibitor present in patients with HUS-TTP following renal transplant 1
Critical Pitfalls to Avoid
- The American Society of Clinical Oncology recommends avoiding platelet transfusion unless there is life-threatening bleeding, as platelet transfusion may worsen thrombotic microangiopathy in patients with HUS-TTP following renal transplant 1
Prognosis and Follow-up
- The American Society of Clinical Oncology recommends monitoring for relapse with weekly hemoglobin and platelet counts until steroid taper is complete in patients with HUS-TTP following renal transplant 1
- The American Society of Nephrology recommends long-term surveillance for chronic kidney disease in the allograft in patients with HUS-TTP following renal transplant 3, 4